journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/29980678/disease-and-outcome-disparities-in-multiple-myeloma-exploring-the-role-of-race-ethnicity-in-the-cooperative-group-clinical-trials
#1
Sikander Ailawadhi, Susanna Jacobus, Rachael Sexton, Alexander K Stewart, Angela Dispenzieri, Mohamad A Hussein, Jeffrey A Zonder, John Crowley, Antje Hoering, Bart Barlogie, Robert Z Orlowski, S Vincent Rajkumar
Multiple myeloma (MM) is an incurable hematologic malignancy with disparities in outcomes noted among racial-ethnic subgroups, likely due to disparities in access to effective treatment modalities. Clinical trials can provide access to evidence-based medicine but representation of minorities on therapeutic clinical trials has been dismal. We evaluated the impact of patient race-ethnicity in pooled data from nine large national cooperative group clinical trials in newly diagnosed MM. Among 2896 patients enrolled over more than two decades, only 18% were non-White and enrollment of minorities actually decreased in most recent years (2002-2011)...
July 6, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29977076/tumor-associated-neutrophils-correlate-with-poor-prognosis-in-diffuse-large-b-cell-lymphoma-patients
#2
LETTER
B Manfroi, J Moreaux, C Righini, F Ghiringhelli, N Sturm, B Huard
No abstract text is available yet for this article.
July 5, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29946154/splanchnic-vein-thrombosis-in-myeloproliferative-neoplasms-treatment-algorithm-2018
#3
Guido Finazzi, Valerio De Stefano, Tiziano Barbui
Myeloproliferative neoplasms (MPNs) are a leading cause of splanchnic vein thrombosis (SVT). SVT is observed in all MPNs and frequently affects young patients. Therapy should be addressed to three main goals: preventing thrombosis recurrence, managing the underlying MPN, and supporting liver dysfunction. Life-long oral anticoagulation with vitamin K antagonists is the cornerstone of the antithrombotic treatment. However, recurrences of SVT or other thrombosis may occur in 15-20% of patients. Direct oral anticoagulants can represent an alternative and preliminary data encourage comparative studies...
June 26, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29946112/antithrombotic-therapy-for-venous-thromboembolism-in-myeloproliferative-neoplasms
#4
Valerio De Stefano, Guido Finazzi, Tiziano Barbui
In myeloproliferative neoplasms (MPNs) the incidence of venous thromboembolism (VTE) is 0.6-1.0 per 100 pt-years, and the rate of recurrence after VTE is 6.0-6.5 per 100 pt-yrs. Vitamin K-antagonists (VKA) reduces the risk of recurrence after VTE at usual sites (i.e., deep venous thrombosis (DVT) of the legs and pulmonary embolism (PE)) by 48-69%, with a rate of recurrent thrombosis per 100 pt-yrs of 3.4-4.7 on VKA and 8.9-9.6 off VKA; VKA discontinuation produces a 2.2-fold increased risk of novel thrombotic events with respect to continuation...
June 26, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29946110/cns-relapse-in-patients-with-dlbcl-treated-with-lenalidomide-plus-r-chop-r2chop-analysis-from-two-phase-2-studies
#5
Ayed O Ayed, Annalisa Chiappella, Levi Pederson, Betsy R Laplant, Angela Giovanna Congiu, Gianluca Gaidano, Michele Spina, Alessandro Re, Federica Cavallo, Gerardo Musuraca, William R Macon, Thomas Witzig, Umberto Vitolo, Grzegorz S Nowakowski
Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in ~ 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan-Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy...
June 26, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29941953/ns-018-reduces-myeloma-cell-proliferation-and-suppresses-osteolysis-through-inhibition-of-the-jak2-and-src-signaling-pathways
#6
LETTER
Ayumi Honda, Kazuya Kuramoto, Tomoko Niwa, Haruna Naito
No abstract text is available yet for this article.
June 25, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29915172/early-bcr-abl1-decline-in-imatinib-treated-patients-with-chronic-myeloid-leukemia-results-from-a-multicenter-study-of-the-chinese-cml-alliance
#7
Jingru Zhang, Yingqiao Wang, Jianxiang Wang, Jianda Hu, Suning Chen, Jie Jin, Ting Liu, Jianfeng Zhou, Yu Hu, Daoxin Ma, Xiaojun Huang, Chunyan Ji, Ming Hou
An early molecular response is spectacularly predictive of outcome in chronic myeloid leukemia (CML) and early response landmarks may identify the high-risk patients likely to be benefit from an early therapy switch. In this study, we evaluated the most relevant cutoffs for early molecular response markers (BCR-ABL1 values at 3 months, log reduction and halving time between diagnosis and 3 months) in 476 first-line imatinib-treated Chinese patients with chronic phase CML. All outcomes were significantly superior for the 324 patients with 3-month BCR-ABL1 ≤10%, so did for the 270 patients with BCR-ABL1 >0...
June 15, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29895953/association-of-mica-and-micb-polymorphisms-with-the-susceptibility-of-leukemia-in-korean-patients
#8
LETTER
In-Cheol Baek, Dong-Hwan Shin, Eun-Jeong Choi, Hyoung-Jae Kim, Jae-Ho Yoon, Byung-Sik Cho, Yoo-Jin Kim, Seok Lee, Woo-Sung Min, Hee-Je Kim, Tai-Gyu Kim
No abstract text is available yet for this article.
June 12, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29895903/integrated-dna-rna-targeted-genomic-profiling-of-diffuse-large-b-cell-lymphoma-using-a-clinical-assay
#9
Andrew M Intlekofer, Erel Joffe, Connie L Batlevi, Patrick Hilden, Jie He, Venkatraman E Seshan, Andrew D Zelenetz, M Lia Palomba, Craig H Moskowitz, Carol Portlock, David J Straus, Ariela Noy, Steven M Horwitz, John F Gerecitano, Alison Moskowitz, Paul Hamlin, Matthew J Matasar, Anita Kumar, Marcel R van den Brink, Kristina M Knapp, Janine D Pichardo, Michelle K Nahas, Sally E Trabucco, Tariq Mughal, Amanda R Copeland, Elli Papaemmanuil, Mathai Moarii, Ross L Levine, Ahmet Dogan, Vincent A Miller, Anas Younes
We sought to define the genomic landscape of diffuse large B-cell lymphoma (DLBCL) by using formalin-fixed paraffin-embedded (FFPE) biopsy specimens. We used targeted sequencing of genes altered in hematologic malignancies, including DNA coding sequence for 405 genes, noncoding sequence for 31 genes, and RNA coding sequence for 265 genes (FoundationOne-Heme). Short variants, rearrangements, and copy number alterations were determined. We studied 198 samples (114 de novo, 58 previously treated, and 26 large-cell transformation from follicular lymphoma)...
June 12, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29895887/risk-stratification-of-smoldering-multiple-myeloma-incorporating-revised-imwg-diagnostic-criteria
#10
Arjun Lakshman, S Vincent Rajkumar, Francis K Buadi, Moritz Binder, Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, David Dingli, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs, Wilson I Gonsalves, Yi Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S Go, Yi Lin, Taxiarchis V Kourelis, Rahma Warsame, John A Lust, Stephen J Russell, Steven R Zeldenrust, Robert A Kyle, Shaji K Kumar
In 2014, the International Myeloma Working Group reclassified patients with smoldering multiple myeloma (SMM) and bone marrow-plasma cell percentage (BMPC%) ≥ 60%, or serum free light chain ratio (FLCr) ≥ 100 or >1 focal lesion on magnetic resonance imaging as multiple myeloma (MM). Predictors of progression in patients currently classified as SMM are not known. We identified 421 patients with SMM, diagnosed between 2003 and 2015. The median time to progression (TTP) was 57 months (CI, 45-72)...
June 12, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29891917/validation-of-the-who-defined-20-circulating-blasts-threshold-for-diagnosis-of-leukemic-transformation-in-primary-myelofibrosis
#11
LETTER
Mythri Mudireddy, Naseema Gangat, Curtis A Hanson, Rhett P Ketterling, Animesh Pardanani, Ayalew Tefferi
No abstract text is available yet for this article.
June 11, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29891916/counseling-patients-with-higher-risk-mds-regarding-survival-with-azacitidine-therapy-are-we-using-realistic-estimates
#12
LETTER
Amer M Zeidan, Maximilian Stahl, Michelle DeVeaux, Smith Giri, Scott Huntington, Nikolai Podoltsev, Rong Wang, Xiaomei Ma, Amy J Davidoff, Steven D Gore
No abstract text is available yet for this article.
June 11, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29891835/long-term-and-low-dose-of-busulfan-is-a-safe-and-effective-second-line-treatment-in-elderly-patients-with-essential-thrombocythemia-resistant-or-intolerant-to-hydroxyurea
#13
LETTER
Rossella Renso, Andrea Aroldi, Pietro Pioltelli, Carlo Gambacorti-Passerini, Elena Maria Elli
No abstract text is available yet for this article.
June 11, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29891838/impact-of-blood-count-recovery-on-outcomes-of-acute-myeloid-leukemia-patients-achieving-morphologic-leukemia-free-state
#14
LETTER
Wen-Yan Cheng, Yong-Mei Zhu, Zhao Liu, Xiang-Qin Weng, Jing-Ni Sui, Yun-Shuo Chen, Shi-Yang Wang, Yang Shen
No abstract text is available yet for this article.
June 7, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29884791/risk-factors-for-venous-thromboembolism-in-patients-with-lymphoma-requiring-hospitalization
#15
LETTER
Stefan Hohaus, Maria Chiara Tisi, Francesca Bartolomei, Annarosa Cuccaro, Elena Maiolo, Eleonora Alma, Francesco D'Alò, Silvia Bellesi, Elena Rossi, Valerio De Stefano
No abstract text is available yet for this article.
June 7, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29921955/leukemic-stem-cell-signatures-identify-novel-therapeutics-targeting-acute-myeloid-leukemia
#16
Isabelle Laverdière, Meaghan Boileau, Andrea L Neumann, Héloïse Frison, Amanda Mitchell, Stanley W K Ng, Jean C Y Wang, Mark D Minden, Kolja Eppert
Therapy for acute myeloid leukemia (AML) involves intense cytotoxic treatment and yet approximately 70% of AML are refractory to initial therapy or eventually relapse. This is at least partially driven by the chemo-resistant nature of the leukemic stem cells (LSCs) that sustain the disease, and therefore novel anti-LSC therapies could decrease relapses and improve survival. We performed in silico analysis of highly prognostic human AML LSC gene expression signatures using existing datasets of drug-gene interactions to identify compounds predicted to target LSC gene programs...
June 6, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29891951/dominant-cytotoxic-nk-cell-subset-within-clpd-nk-patients-identifies-a-more-aggressive-nk-cell-proliferation
#17
LETTER
Gregorio Barilà, Antonella Teramo, Giulia Calabretto, Chiara Ercolin, Elisa Boscaro, Valentina Trimarco, Samuela Carraro, Matteo Leoncin, Cristina Vicenzetto, Anna Cabrelle, Monica Facco, Francesco Piazza, Gianpietro Semenzato, Renato Zambello
No abstract text is available yet for this article.
June 5, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29891941/rare-variants-in-fanconi-anemia-genes-are-enriched-in-acute-myeloid-leukemia
#18
LETTER
Kyaw Ze Ya Maung, Paul J Leo, Mahmoud Bassal, Debora A Casolari, James X Gray, Sarah C Bray, Stephen Pederson, Deepak Singhal, Saumya E Samaraweera, Tran Nguyen, Gökhan Cildir, Mhairi Marshall, Adam Ewing, Emma L Duncan, Matthew A Brown, Russell Saal, Vinay Tergaonkar, Luen Bik To, Paula Marlton, Devinder Gill, Ian Lewis, Andrew J Deans, Anna L Brown, Richard J D'Andrea, Thomas J Gonda
No abstract text is available yet for this article.
June 1, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29880847/the-aspirin-regimens-in-essential-thrombocythemia-ares-phase-ii-randomized-trial-design-implementation-of-the-serum-thromboxane-b-2-assay-as-an-evaluation-tool-of-different-aspirin-dosing-regimens-in-the-clinical-setting
#19
Valerio De Stefano, Bianca Rocca, Alberto Tosetto, Denise Soldati, Giovanna Petrucci, Eloise Beggiato, Irene Bertozzi, Silvia Betti, Giuseppe Carli, Monica Carpenedo, Daniele Cattaneo, Viviana Cavalca, Alfredo Dragani, Elena Elli, Guido Finazzi, Alessandra Iurlo, Giuseppe Lanzarone, Laura Lissandrini, Francesca Palandri, Chiara Paoli, Alessandro Rambaldi, Paola Ranalli, Maria Luigia Randi, Alessandra Ricco, Elena Rossi, Marco Ruggeri, Giorgina Specchia, Andrea Timillero, Linda Turnu, Nicola Vianelli, Alessandro M Vannucchi, Francesco Rodeghiero, Carlo Patrono
Once-daily (od), low-dose aspirin (75-100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions...
June 1, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29795444/the-oncogenic-fusion-protein-cbfb-smmhc-downregulates-cd48-to-evade-nk-cell-recognition
#20
LETTER
Shira Kahlon, Dorin Shreibman, Tamar Unger, Dina Ben-Yehuda, Shlomo Elias
No abstract text is available yet for this article.
May 24, 2018: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"